Design to come?

WP_Post Object
(
    [ID] => 1100
    [post_author] => 3
    [post_date] => 2021-12-10 13:41:12
    [post_date_gmt] => 2021-12-10 18:41:12
    [post_content] => 
    [post_title] => Intensity Therapeutics Reports Promising Early Efficacy Results Using INT230-6 as a Monotherapy or in Combination with Pembrolizumab in Metastatic Breast Cancer at the 2021 San Antonio Breast Cancer Symposium®
    [post_excerpt] => 
    [post_status] => publish
    [comment_status] => closed
    [ping_status] => closed
    [post_password] => 
    [post_name] => intensity-therapeutics-reports-promising-early-efficacy-results-using-int230-6-as-a-monotherapy-or-in-combination-with-pembrolizumab-in-metastatic-breast-cancer-at-the-2021-san-antonio-breast-cancer-s
    [to_ping] => 
    [pinged] => 
    [post_modified] => 2022-02-03 13:42:04
    [post_modified_gmt] => 2022-02-03 18:42:04
    [post_content_filtered] => 
    [post_parent] => 0
    [guid] => https://vcapital.com/?post_type=news&p=1100
    [menu_order] => 0
    [post_type] => news
    [post_mime_type] => 
    [comment_count] => 0
    [filter] => raw
)